Valuation: Lexicon Pharmaceuticals, Inc.

Market Cap 703M 626M 580M 526M 988M 66.6B 1B 6.96B 2.73B 34.85B 2.64B 2.58B 111B P/E 2026 *
-9.29x
P/E 2027 * -7.9x
Enterprise Value 703M 626M 580M 526M 988M 66.6B 1B 6.96B 2.73B 34.85B 2.64B 2.58B 111B EV / Sales 2026 *
18.9x
EV / Sales 2027 * 41.5x
Free-Float
98.45%
Yield 2026 *
-
Yield 2027 * -
09-09 Lexicon Pharmaceuticals, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 11:20 AM
08-31 Lexicon Pharmaceuticals Announces Results from Post Hoc Soloist-Whf Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure CI
08-24 Lexicon Pharma Earns $10 Million Milestone Payment from Novo Nordisk DJ
08-24 Lexicon Pharmaceuticals Gets $10 Million Novo Nordisk Milestone Payment for LX9851 MT
08-06 Lexicon Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 06, 2026
08-06 Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-06 Earnings Flash (LXRX) Lexicon Pharmaceuticals Posts Q2 Loss $0.07 a Share, vs. FactSet Est of $0.05 Loss MT
08-06 Earnings Flash (LXRX) Lexicon Pharmaceuticals, Inc. Reports Q2 Revenue $692,000, vs. FactSet Est of $4.0M MT
07-27 Lexicon Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Sonata-Hcm Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy CI
07-27 Lexicon Pharmaceuticals Completes Enrollment in Trial of Potential Hypertrophic Cardiomyopathy Treatment MT
06-29 Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell Small Cap Comp Growth Benchmark CI
06-29 Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 2000 Index CI
06-29 Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 2500 Growth Benchmark CI
1 day+1.94%
1 week-1.86%
Current month-15.73%
1 month-22.93%
3 months-32.19%
6 months-14.13%
Current year+37.39%
1 week 1.51
Extreme 1.5102
1.68
1 month 1.51
Extreme 1.5102
2.2
Current year 1.1
Extreme 1.1
2.68
1 year 1.1
Extreme 1.1
2.68
3 years 0.28
Extreme 0.2836
3.73
5 years 0.28
Extreme 0.2836
5.79
10 years 0.28
Extreme 0.2836
18
Manager TitleAgeSince
Chief Executive Officer 56 2024-07-07
Director of Finance/CFO 59 2025-01-01
Chief Tech/Sci/R&D Officer - 2025-01-31
Director TitleAgeSince
Chairman 83 2004-12-31
Chairman 71 2012-02-26
Director/Board Member 67 2007-08-27
Date Insider Type Main position Quantity % Market Cap. Importance
6/3/26 Exercice

Director

178,624 0.0402%
6/3/26 Exercice

Director

178,624 0.0402%
6/3/26 Exercice

Director

178,624 0.0402%
Change 5-day change 1-year change 3-year change Capi.($)
+1.94%-1.86%+3.95%+39.82% 703M
+0.79%-6.16%+49.32%+74.50% 66.34B
-0.75%+6.22%+11.35%+89.80% 52.92B
-0.36%+4.07%+6.68%+72.23% 54.82B
+0.74%+2.75%+26.31%+45.29% 44.09B
+3.87%+10.15%+20.69%+132.73% 43.72B
+7.91%+4.30%+263.91%+602.72% 42.13B
-0.40%+9.85%+17.04%+59.17% 33.96B
-1.78%-1.13%+36.54%+6.57% 26.17B
+0.13%+4.72%+35.40%+25.28% 23.37B
Average +1.20%+0.89%+47.12%+114.81% 38.82B
Weighted average by Cap. +1.21%+1.98%+50.97%+127.88%

Financials

2026 *2027 *
Net sales 37.17M 33.09M 30.67M 27.79M 52.22M 3.52B 53.1M 368M 145M 1.84B 139M 137M 5.88B 16.93M 15.07M 13.96M 12.65M 23.78M 1.6B 24.18M 168M 65.83M 839M 63.5M 62.18M 2.68B
Net income -73.77M -65.66M -60.85M -55.14M -104M -6.99B -105M -730M -287M -3.66B -277M -271M -11.67B -97.05M -86.38M -80.06M -72.55M -136M -9.19B -139M -961M -377M -4.81B -364M -356M -15.35B
Net Debt - -
Projected Income Statement - Annual - Lexicon Pharmaceuticals, Inc.
Logo Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The Company develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The Company also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders.
Employees
81
Date Price Change Volume
26-10-20 US$1.580 +1.94% 1,410,976
26-10-19 US$1.550 +1.97% 1,723,494
26-10-16 US$1.520 -7.88% 2,014,478
26-10-15 US$1.650 +3.12% 1,433,569
26-10-14 US$1.600 -0.62% 1,905,894
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Lexicon Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1.580USD
Average target price
4.547USD
Spread / Average Target
+187.76%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Lexicon Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. LXRX Stock